PAX5 and diffuse large B-cell lymphoma: To validate these findings, we made use of RNA-seq data sets (The Cancer Genome Atlas and Gene Expression Omnibus) to examine Pax-5 3′UTR editing in the most common B-cell malignancies characterized with aberrant Pax-5 (ex: diffused large B-cell lymphoma/DLBCL [16,49] and chronic lymphocytic leukemia/CLL [50]) in comparison to healthy primary B-lymphocytes.